Q-omics provides the consensus-scored IL18RAP profile across patient tissues and cancer cell-line models. IL18RAP expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IL18RAP is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, IL18RAP RNA expression shows 19,148 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where IL18RAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL18RAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL18RAP survival associations across molecular data types. IL18RAP RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL18RAP RNA expression–survival associations across cancer types. High IL18RAP expression shows favorable associations in SKCM, LIHC, HNSC, BLCA, CESC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IL18RAP RNA expression.
This table summarizes IL18RAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IL18RAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL18RAP shows lower tumor expression in LUAD, LUSC, COAD and BRCA and higher tumor expression in KIRC and KICH. The KIRC box plot shows higher IL18RAP RNA expression in tumor versus normal tissue (log2 FC = +0.778, t-test p < 0.001).
This table shows molecular features associated with IL18RAP in patient tissues and cancer cell lines. In patient samples, IL18RAP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL18RAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
